ArticleTurkish journal of biology = Turk biyoloji dergisi2024
Combinational therapy of all-trans retinoic acid (ATRA) and sphingomyelin induces apoptosis and cell cycle arrest in B16F10 melanoma cancer cells.
Article in Turkish journal of biology = Turk biyoloji dergisi, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Significance of Vitamins A and E in Cancer Progression and Prevention.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: Melanoma arises from the uncontrolled multiplication of melanocytes, and poses an escalating global health concern. Despite the importance of early detection and surgical removal for effective treatment, metastatic melanoma poses treatment challenges, with limited options. Among optional therapies, including chemotherapy and immunotherapy, all-trans retinoic acid (ATRA), a natural metabolite of vitamin A, has shown promise in treating melanoma by inducing differentiation, apoptosis, growth arrest, and immune modulation in melanoma cells. However, ATRA treatment alone can lead to resistance and relapse. Furthermore, sphingomyelin (SM) was implicated in the inhibition of cell proliferation, differentiation, and apoptotic cell death during melanoma progression. Materials and methods: The combinational anticancer effects of ATRA and SM on an in vitro B16F10 melanoma model were investigated based on cell viability, apoptotic cell death, cell cycle progression, and gene expression levels; whereas the safety properties of the treatments were tested on RAW264.7 macrophages. Results: The combination of 123 μM of ATRA + 136 μM of SM was the most effective treatment, showing a 50% reduction in cell proliferation, leading to 53.91% apoptotic cell death in 48 h, and G2/M phase-cell cycle arrest in the B16F10 cells. While 123 μM of ATRA alone did not change the caspase 3 and Bax gene expressions, the combinational ATRA + SM treatment resulted in 2- and 5-fold increases in the gene expression level, respectively. A 13-fold increase in cyclin-dependent kinase inhibitor 2A was observed with the combinational ATRA + SM treatment, while suppressing the programmed death ligand 1 (PD-L1) expression by 0.5-fold. Conclusion: Combinational ATRA and SM therapy could be a promising therapeutic approach for melanoma, potentially improving efficacy, while reducing toxicity to healthy cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.